Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Isis Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Isis Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Isis Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Isis Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Isis Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Isis Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Isis Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Isis Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Isis Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Isis Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Isis Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Isis Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Isis Pharmaceuticals, Inc. Snapshot 7 Isis Pharmaceuticals, Inc. Overview 7 Key Information 7 Key Facts 7 Isis Pharmaceuticals, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Isis Pharmaceuticals, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Isis Pharmaceuticals, Inc. - Pipeline Products Glance 18 Isis Pharmaceuticals, Inc. - Late Stage Pipeline Products 18 Phase III Products/Combination Treatment Modalities 18 Isis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 19 Phase II Products/Combination Treatment Modalities 19 Phase I Products/Combination Treatment Modalities 20 Isis Pharmaceuticals, Inc. - Early Stage Pipeline Products 21 Preclinical Products/Combination Treatment Modalities 21 Discovery Products/Combination Treatment Modalities 22 Isis Pharmaceuticals, Inc. - Drug Profiles 23 ISIS-TTRRx 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ISIS-APOCIIIRx 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ISIS-CRPRx 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ISIS-EIF4ERx 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ISIS-FXIRx 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ISIS-GCCRRx 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ISIS-GCGRRx 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ISIS-PTP1BRx 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 ISIS-SMNRx 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ISIS-ANGPTL3 Rx 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ISIS-APOARx 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ISIS-FGFR4Rx 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ISIS-HBVRx 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ISIS-SOD1Rx 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CideB Antisense Oligonucleotide 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 ISIS-AATRx 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ISIS-DGAT2Rx 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ISIS-DMPKRx 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ISIS-FVIIRx 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 ISIS-GSK4 Rx 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 ISIS-HTTRx 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ISIS-PKKRx 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Antisense Oligonucleotides for Neurology 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Isis Pharmaceuticals, Inc. - Pipeline Analysis 48 Isis Pharmaceuticals, Inc. - Pipeline Products by Target 48 Isis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 50 Isis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 51 Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 52 Isis Pharmaceuticals, Inc. - Recent Pipeline Updates 54 Isis Pharmaceuticals, Inc. - Dormant Projects 67 Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products 68 Discontinued Pipeline Product Profiles 68 ISIS-104838 68 ISIS-113715 68 ISIS-14803 68 ISIS-2503 68 ISIS-5132 69 ISIS-EIF4ERx 69 Isis Pharmaceuticals, Inc. - Company Statement 70 Isis Pharmaceuticals, Inc. - Locations And Subsidiaries 71 Head Office 71 Other Locations & Subsidiaries 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 73 Disclaimer 73
List of Tables Isis Pharmaceuticals, Inc., Key Information 7 Isis Pharmaceuticals, Inc., Key Facts 7 Isis Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9 Isis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11 Isis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12 Isis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 13 Isis Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 14 Isis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 15 Isis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 16 Isis Pharmaceuticals, Inc. - Phase III, 2014 18 Isis Pharmaceuticals, Inc. - Phase II, 2014 19 Isis Pharmaceuticals, Inc. - Phase I, 2014 20 Isis Pharmaceuticals, Inc. - Preclinical, 2014 21 Isis Pharmaceuticals, Inc. - Discovery, 2014 22 Isis Pharmaceuticals, Inc. - Pipeline by Target, 2014 49 Isis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 50 Isis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 51 Isis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 53 Isis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 54 Isis Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 67 Isis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 68 Isis Pharmaceuticals, Inc., Subsidiaries 71
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
